U.S. markets open in 10 minutes

Bionano Genomics, Inc. (BNGO)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
0.6171-0.0129 (-2.05%)
At close: 4:00PM EDT

0.6299 +0.01 (2.07%)
Before hours: 9:15AM EDT

Sign in to post a message.
  • D
    DVM
    Bionano and Hancock Jaff Labs are my biggest holdings.
    Wishing you all the best, longs!
    Bullish
  • G
    Gekko
    $OCGN conversation
    Before you know it the short volume will fall below 5% and $BNGO's share price will take off. Look how it has been falling on average almost 2.5% daily for the last 7 trading days. From 38% (on 9/9) to 21% (on 9/18). IMO $0.80 possible by EOW and $1 by EOY no problem. This TECH is disruptive and soon to spread wildly around the globe much like a pandemic. $BNGO is on the front lines of the current pandemic we find ourselves in and will be one PART of the solution. Buy a couple hundred shares, or even better buy a couple thousand and you can retire on it in 30 years. That's my plan! IRA baby!
    Bullish
  • E
    ESG Trading
    They’re hiring 2 new regional business managers in the US. That’s a good sign, ramping up growth in both the US and Europe!
  • T
    TruTrader
    In case you don't like clicking links....you ABSOLUTELY have to read the new PR. This is the calm before the storm. Better go inside and prepare shorts and bears....SAN DIEGO, Sept. 16, 2020 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced today that its Saphyr system has been adopted through reagent-rentals by four additional institutions in Europe: the Department of Human Genetics, Ruhr University Bochum and the Clinic for Pediatrics III, University Hospital Essen in Germany and the Institute for Medical Genetics and Pathology at the University Hospital Basel and the Institute for Medical Genetics, Zurich in Switzerland.At each medical institute, integration of Bionano?s Saphyr will be used to help validate Bionano?s genome imaging technology against standard methods in cytogenetic analysis as a path to streamline the diagnostics workflow for constitutional genetic conditions and for cancer diagnostics. Genome analysis with Saphyr consolidates into a single assay the testing that typically requires three separate structural variant analysis techniques (karyotyping, fluorescence in situ hybridization and chromosomal microarrays). With its demonstrated sensitivity as low as approximately 1% allele fraction, we believe Saphyr meets or exceeds the performance requirements to help drive adoption.?Building on the recent momentum of Saphyr?s integration within multiple leading medical institutes in Italy, Spain and France, we are encouraged by the continued growth and expansion of Saphyr adoption most recently in Germany and Switzerland, particularly during a challenging summer in Europe.? said Erik Holmlin, Ph.D., chief executive officer of Bionano. ?It's great to see this momentum, which we hope serves as evidence that markets continue to open up and that our recently unveiled reagent rental model is well-received as something that lowers the barrier to Saphyr adoption. Combined with the ongoing validation study at Medicover MVZ, Munich, which is designed to obtain national accreditation for Saphyr in constitutional cytogenetics in Germany, we remain enthusiastic about continued growth in Saphyr adoption for applications in cytogenetics.?Dr. Huu #$%$ Nguyen, director of Ruhr University Bochum?s Department of Human Genetics, stated, ?My team and I are planning to validate Bionano?s technology and plan to integrate Saphyr into our workflow. Our aim is to substitute or even replace some older generation technologies to be more efficient and more accurate in our daily work."Dr. Nils von Neuhoff, professor of molecular genetics at the University Hospital Essen added, ?The Hospital Essen and my team are planning to validate the Saphyr system. We are the national reference lab for diagnostics of childhood AML. Among our focuses is the identification of the leukemic stem cell of AML. We plan to analyze this cell, which is central to the disease, using new genetic analysis technologies, including Saphyr. The output of this technology can be used to create genetic profiles of the tumors, optimize therapies and develop new active substances for patients.?Bionano plans to continue driving adoption of the Saphyr System globally and replace or supplement older, outdated cytogenetic technologies to optimize diagnostic outcomes that may enable medical professionals to provide superior care to patients.
  • p
    privledgedinsider
    IMHO This company will flourish as this new technology expands to the rest of the medical communities in this sector. They will either be bought out or end up in the $50 p/s arena within a short time. This is huge to become the standard in any medical field or sector. No where but up from here!!
  • M
    Michael
    Things are coming together.... 7 new locations in Europe over the past week, covering also more conventional tests, which will drive adoption and coverage. The last purchase of the company will add 7-10 million in annual sales, plus the 6-12 million in annual sales, we will be between 15-22 million this year, in a bad year.

    From what I read, they cover a unique niche, so they will be target for takeover, or they will be growing organically over time. Hope that growth picks up, this will happen with their lease model, plus Saphyr placements and regular genomics tests.

    this story is for sure in its early phases
  • D
    Dan
    If you have a Genomeweb subscription, there is a solid article released today on Bionano.
  • T
    TInku
    In the battle of ecosystems and platforms, we know that BNGO has licensed patents from PACB. We also know that the rise of 10x is because of cheap ILMN reads as underlying platform. As tide is shifting towards PACB, BNGO will be in focus. Funds like ARKG have to notice BNGO and start the price in right direction. Best of luck to BNGO longs. BNGO has at least picked the right baseline NGS platform.
    Bullish
  • T
    Tony
    Do you guys not see STRATEGIC MOVES? CEO knows what hes doing


    Bionano Genomics Expands Its Diagnostic Testing Menu with Launch of Lineagen’s EpiPanelDx PLUS Gene Panel Test that Identifies Genetic Conditions Related to Epilepsy

    EpiPanelDx PLUS adds to Lineagen’s expanding menu of diagnostic tests for children with developmental disorders and provides an offering designed specifically for patients that have experienced seizures or other epilepsy-related symptoms
    SAN DIEGO, Sept. 14, 2020 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the release of EpiPanelDx PLUS™ by its diagnostics services business, Lineagen. The new laboratory developed test (LDT) and associated clinical support bolsters Lineagen’s diagnostic services for physicians providing care for pediatric patients with neurodevelopmental disorders (NDDs). EpiPanelDx PLUS is based on a proprietary panel of 223 genes associated with epilepsy-related conditions, more genes than typically found on epilepsy panels available from other service providers and customized for Lineagen’s core market of neurodevelopmental disorders.
    Epilepsy refers to an array of neurological disorders characterized by involuntary seizures and affects approximately 1.2% of the population, or 3.4 million people, in the United States. It is frequently comorbid with other NDDs of childhood development, including intellectual disability and autism spectrum disorder and also can co-occur with neuro-behavioral disorders such as attention deficit hyperactivity disorder (ADHD). Collectively, NDDs represent the most common form of developmental disorder with an estimated prevalence of 1 out of 6 children affected in industrialized countries. Lineagen’s current menu of FirstStepDx PLUS® chromosomal microarray and NextStepDx PLUS™ whole exome sequencing offers leading molecular diagnostic tests designed to help pediatricians and pediatric neurodevelopmental specialists manage their patients with NDDs. Offering such physicians a test for epilepsy allows Lineagen to more comprehensively serve their needs.
    “Identifying the underlying genetic variants that may explain the underlying cause of seizures is extremely important because it informs multiple aspects of clinical care,” said Alka Chaubey, PhD, Chief Medical Officer of Bionano Genomics. “This test allows for personalized treatment of the patient, can predict the recurrence risk for other members of the family, and ends the diagnostic odyssey, which for many families can mean years of doctor visits, invasive tests, and failed or even harmful treatments.”
    EpiPanelDx PLUS is designed for patients who have experienced seizures, infantile spasms, encephalopathy, or febrile seizures, and has an expected 30% diagnostic yield. Lineagen also offers testing to the parents of the patients. By including the analysis of the genomes of one or both biological parents of the patient from the start, it is possible to increase the detection rate of disease-causing variants and inform on recurrence risk for the family. EpiPanelDx PLUS has been curated based on thorough literature review and includes genes with pathogenic variants identified in more than 2,000 epileptic patients tested by Lineagen.
    The use of a targeted gene panel such as EpiPanelDx PLUS fits the testing strategy that is recommended by the American Academy of Neurology and complements existing genetic tests offered by Lineagen such as FirstStepDx PLUS chromosomal microarray and NextStepDx PLUS whole exome sequencing, which are recommended for patients who show a wider array of neurological symptoms. To help tailor medical management, Lineagen also offers pharmacogenomic testing which includes certain genes that are responsible for the metabolism of important anti-epileptic or anticonvulsant drugs prescribed for epilepsy.
    “We already have a depth of knowledge on epilepsy genetics,” added Dr Chaubey. “We recently tested a 3-year-old girl with muscle spasms and seizures, as well as her parents, and identified a mutation in the SLC2A1 gene. Based on these results, the doctor was able to treat the child with a simple ketogenic diet and over-the-counter supplementation. If she had instead been treated with barbiturates, at one time a standard treatment for epilepsy patients and now contraindicated in patients with this specific genetic condition, her seizures likely would have gotten worse. This case is one of many where results of a genetic test enabled the family and treating physician to significantly improve the quality of life of the child and family.”
    Bionano Genomics provides unparalleled structural variation detection for genetic disease research, cancer research & cytogenomics with genome imaging technology.
    Bionano Genomics provides unparalleled structural variation detection for genetic disease research, cancer research & cytogenomics with genome imaging technology.
    bionanogenomics.com
    Bullish
  • O
    Oh
    It's very easy to get pretentious and not objective regarding the stock price. I see other biotechs boards and I feel very encouraged by the fact that I chose an investment that is not dependent on fda approvals and results of experiments. I really think that in this aspect $bngo is a solid investment.
    Bullish
  • P
    Prateek
    Bionano has till December to trade above 1 dollar and be compliant with Nasdaq listing criterion. I think we can see a jump in price now... Good times ahead..
  • j
    joe
    The Press Releases, if true, are nothing short of remarkable. Why this stock is not responding big to the upside is puzzling.
  • T
    TruTrader
    Even when you buy the lows...you have to buy on strength. Short volume is down from the daily average 6%. That's a sign. This is the time to buy if you want IN or need to average down. September has 2 analyst consensus median price target this time next year is $1.50. High side is $2. I think that's conservative given the disruptive technology. The big boys that are no longer the standard are doing everything they can to keep this stock down. You think this short volume is coming from savvy individual investors like you and I who know this is life changing on a global scale and can't wait for it to be adopted for even just the sake of our own families and loved ones. Don't kid yourself, this consistent and intense daily salvo of a 34% average daily short volume is a coordinated attack from those who are enemies of this amazing company. And in their initial endeavors so to speak, $BNGO is focused most intensely in the areas of Covid & Pediatrics. I have been adding nearly 600-1000 shares daily depending on the price movement with my eye on this time next year and long term capital gains tax vs. short term gains tax. With that said, VOTE YES on the additional shares being issued. $BNGO needs a barge full of cash to fund growth and expansion. Taking over the WORLD technologically speaking...is the most expensive endeavor imaginable. JMHumbleO
    ! GLTA!!! DYODD!!!
  • d
    dick
    I heard kraken was last seen in India trying to find money to cover his short margins! 😂
    Bullish
  • T
    TruTrader
    Bionano Genomics Continues to See Expansion in the Adoption of Saphyr for Digital Cytogenetics at Leading Medical Institutions!!!

    https://finance.yahoo.com/news/bionano-genomics-continues-see-expansion-120000371.html
    Bullish
  • D
    DVM
    SAN DIEGO, Sept. 14, 2020 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the release of EpiPanelDx PLUS™ by its diagnostics services business, Lineagen. The new laboratory developed test (LDT) and associated clinical support bolsters Lineagen’s diagnostic services for physicians providing care for pediatric patients with neurodevelopmental disorders (NDDs).
    Bullish
  • P
    Prateek
    Dr. Huu #$%$ Nguyen, director of Ruhr University Bochum?s Department of Human Genetics, stated, ?My team and I are planning to validate Bionano?s technology and plan to integrate Saphyr into our workflow. Our aim is to substitute or even replace some older generation technologies to be more efficient and more accurate in our daily work."
  • P
    Prateek
    Nobody's an expert here. Guys don't make judgements based on yahoo chat forums. This is a great stock and will go up no matter what. Just a patience game. Hold it. Mute haters.
  • M
    Me2Big
    BNGO positive : Saphyr is a revolutionary product that will be needed by every genetics research lab, many drugs companies and universities.
    BNGO negative : Cash burn (needs to issue more shares quickly to cover costs). C19 virus closed labs worldwide, causing about 45% decrease in income. BNGO "ripped off" by non-payments of apprx. $1.3 million ("the Company recognized bad debt expense of $1.3 million during the six months ended June 30, 2020").
    I Would love to buy BNGOW (.86 warrants expiring Sept. 2023) and see the shares go to $3, but would first like to see how this C19 shutdown is resolved, how many shares are going to need to be issued to pay the bills etc.
    Neutral
  • A
    Albert
    BNGO
    Current Quarter Growth Estimates @ 91.50%, however, before or after the 100% reader introduced and or BNGO's new gold standard possible label?
    M&A ?